Paricalcitol NDC 49483-689

NDC codes

FDA NDC Directory

Product NDC (as listed)49483-689Labeler and product segments. Claims need a package NDC.

Product NDC at billing width49483-0689Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
49483-689-03	49483068903	30 CAPSULE, LIQUID FILLED in 1 BOTTLE (49483-689-03)Marketed from Jan 3, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Paricalcitol
Generic name (nonproprietary): paricalcitol
Active ingredients: Paricalcitol — 4 ug/1
Dosage form: Capsule, Liquid filled
Route: Oral
Labeler: TIME CAP LABORATORIES, INC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 204948
Marketing start: Jan 3, 2017
Listing expires: Dec 31, 2026
Other FDA classes: Ergocalciferols (Chemical structure)
Identifiers: Product ID 49483-689_eed565d0-059d-eef6-e053-2a95a90ac962SPL ID eed565d0-059d-eef6-e053-2a95a90ac962SPL set ID f593b575-7537-4531-87fc-c1b0814fd018RxCUI 577315, 577317, 577324UNII 6702D36OG5UPC 0349483687033, 0349483688030, 0349483689037
Pharmacologic class: Vitamin D2 Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N449483068903 followed by a unit qualifier and the quantity

Package 49483-0689-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 2, 2022.

Indications (excerpt from the label)

1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (Paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Chronic Kidney Disease Stage 5 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD)…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 204948

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 204948
Product	Strength	Form · route	Labeler	Product NDC
Paricalcitol	Paricalcitol 1 ug/1	Capsule, Liquid filledOral	TIME CAP LABORATORIES, INC	49483-687
Paricalcitol	Paricalcitol 2 ug/1	Capsule, Liquid filledOral	TIME CAP LABORATORIES, INC	49483-688
Paricalcitol	Paricalcitol 2 ug/1	Capsule, Liquid filledOral	MARKSANS PHARMA LIMITED	25000-014
Paricalcitol	Paricalcitol 1 ug/1	Capsule, Liquid filledOral	MARKSANS PHARMA LIMITED	25000-012
Paricalcitol	Paricalcitol 4 ug/1	Capsule, Liquid filledOral	MARKSANS PHARMA LIMITED	25000-017